Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B
Background Systemic corticosteroid is used for different medical conditions and may cause hepatitis B virus (HBV) reactivation. Aims To study the impact of duration and peak dose of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B (CHB). Methods All patients who rec...
Gespeichert in:
Veröffentlicht in: | Liver international 2019-02, Vol.39 (2), p.271-279 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Systemic corticosteroid is used for different medical conditions and may cause hepatitis B virus (HBV) reactivation.
Aims
To study the impact of duration and peak dose of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B (CHB).
Methods
All patients who received corticosteroid from January 2001 to December 2004 were retrieved from the Hospital Authority, Hong Kong. We stratified patients by daily dose prednisolone equivalents (40 mg) and durations (28 days). The primary endpoint was hepatitis flare (alanine aminotransferase >2×upper limit of normal, ie 80 IU/L) at 1 year.
Results
A total of 85 763 patients fulfilled the inclusion criteria (5254 CHB, 80 509 non‐CHB). CHB patients had higher risk of hepatitis flare (388/5254 [7.8%]) than those without CHB (2728/80 509 [4.2%]; P 40 mg compared to |
---|---|
ISSN: | 1478-3223 1478-3231 |
DOI: | 10.1111/liv.13953 |